- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00500058
A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18
July 24, 2017 updated by: GlaxoSmithKline
A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 (SB-485232) Administered by Intravenous Infusion in Combinationwith Rituximab in Adult Patients With B Cell Non-Hodgkin'sLymphoma"
The purpose is to identify a dose of SB-485232 which is safe, tolerable and effective when used in combination with Rituximab in patients with non-Hodgkin's lymphoma (NHL).
This study will use a standard treatment regimen of Rituximab in combination with rising doses of SB-485232.
The dose selected from this study will be used in a future studies.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- GSK Investigational Site
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically confirmed diagnosis of any subtype of CD20+ B cell NHL. Subjects must have disease that progressed after standard therapy or for which there is no effective standard therapy (including high-dose therapy and autologous stem cell transplantation). NOTE: If the subject has had a prior autologous stem cell transplant, it must have occurred at least three months prior to screening and the subject must be fully recovered from any acute toxicities.
- Prior treatment with Rituximab is allowed, provided it was completed at least six months before study enrollment.
- Male or female ≥ 18 years of age.
- Measurable or evaluable disease.
- Predicted life expectancy of at least 12 weeks.
- ECOG Performance Status of 0 or 1.
- No chemotherapy, immunotherapy, hormonal therapy, or biological therapy for cancer, radiotherapy, or surgical procedures (except for minor surgical procedures) within four weeks before beginning treatment with SB-485232 (6 weeks for nitrosoureas and mitomycin C). Subjects must have recovered from toxicities (incurred as a result of previous therapy) sufficiently to be entered into a Phase I study.
- A signed and dated written informed consent form is obtained from the subject.
- The subject is able to understand and comply with protocol requirements, timetables, instructions and protocol-stated restrictions.
The subject is likely to maintain good venous blood access for PK and PD sampling throughout the study.
A female is eligible to enter and participate in the study if she is of:
a. non-childbearing potential (i.e., physiologically incapable of becoming pregnant) including any female who:
- has had a hysterectomy,
- has had a bilateral oophorectomy (ovariectomy),
- has had a bilateral tubal ligation,
- is post-menopausal (demonstrate total cessation of menses for greater than 1year), If amenorrheic for less than one year, post-menopausal status will be confirmed by serum follicle stimulating hormone (FSH) and oestradiol concentrations at screening. or, b. childbearing potential, has a negative serum pregnancy test at the Screen Visit, and agrees to one of the following GSK acceptable contraceptive methods:
any intrauterine device (IUD) with a documented failure rate of less than
1% per year.
- vasectomized partner who is sterile prior to the female subject's entry and is the sole sexual partner for that female.
- oral contraceptive (either combined or progesterone only).
- because of the unacceptable failure rate of barrier (chemical and/or physical) methods, the barrier method of contraception must only be used in combination with other acceptable methods described above.
- Adequate organ function,
Exclusion Criteria:
- Women who are pregnant or are breast-feeding.
- Significant cardiac, pulmonary, metabolic, renal, hepatic, gastrointestinal or autoimmune conditions that in the opinion of the investigator and/or GSK medical monitor, places the subject at an unacceptable risk as participant in this trial.
- The subject has diabetes mellitus with poor glycemic control.
- The subject has a history of human immunodeficiency virus (HIV) or other immunodeficiency disease.
- The subject has positive Hepatitis B surface antigen.
- Corrected QT interval (QTc) > 480msec.
- The subject has a history of a severe infusion related reaction or tumor lysis syndrome following treatment with Rituximab (Section 10.2.2).
- The subject has a circulating malignant cell count > 25,000/mm3 in peripheral blood.
- The subject has known anaphylaxis or IgE-mediated hypersensitivity to murine proteins.
- The subject has an acute infection or severe or uncontrolled infections requiring systemic antibiotic therapy.
- Any serious medical or psychiatric disorder that would interfere with subject safety or informed consent.
- Known leptomeningeal disease or evidence of prior or current metastatic brain disease. Routine screening with central nervous system (CNS) imaging studies (CT or MRI) is required only if clinically indicated.
- Receiving concurrent chemotherapy, immunotherapy, radiotherapy, or investigational therapy.
- Oral corticosteroids within 14 days of study entry.
- History of alcohol abuse within six months of screening or alcohol consumption in the past six months exceeding seven drinks/week for women and 14 drinks/week for men (where 1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor).
- History of ventricular arrhythmias requiring drug or device therapy.
- Any unresolved or unstable serious toxicity from prior administration of another investigational drug.
- Any investigational drug within 30 days or five half-lives (whichever is longer) preceding the first dose of SB-485232.
- Donation of blood in excess of 500 mL within a 56-day period prior to dosing.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SB-485232+Rituximab
Rituximab 375 milligrams per square meter (mg/m^2) will be administered to subjects with CD20+ B cell lymphoma by intravenous (IV) infusion once a week for four consecutive weeks on Day 1 of Weeks 1 to 4. SB-485232 will be administered by IV infusion over a 2 hour period, at doses ranging from 1 microgram (μg)/kilogram (kg) to 100 μg/kg.
SB-485232 will be given once a week for 12 consecutive weeks on Day 2 of Weeks 1 to 4 and Day 2 (± 1 day) of Weeks 5 to 12. SB-485232 will be infused at least 24 hours after the Rituximab infusion was started.
|
SB-485232 for injection, 7 mg/vial, will be available as a lyophilized cake.
It will be reconstituted with 1.4 mL of water for injection.
Each vial of this drug product is a clear, colorless solution containing 5 mg/mL of SB-485232.
Rituximab 375 mg/m^2 will be administered by IV infusion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
safety/tolerability of combination treatment for 4 weeks safety/tolerability of SB-485232 for additional 8 weeks
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
assess blood values of combination treatment for 4 weeks assess blood values of SB-485232 for additional 8 weeks
Time Frame: 12 weeks
|
12 weeks
|
Pharmacokinetic parameters for SB-485232 and Rituxan: AUCtau, Cmax, and Cmin.
Time Frame: 12 weeks
|
12 weeks
|
Pharmacodynamic biomarker responses:
Time Frame: 12 weeks
|
12 weeks
|
Plasma IFN-γ, GMCSF, IP-10, MIG, and MCP-1 changes
Time Frame: from baseline and predose
|
from baseline and predose
|
Plasma IL-18BP change
Time Frame: from baseline
|
from baseline
|
PBMC phenotype changes
Time Frame: from baseline and pre-dose
|
from baseline and pre-dose
|
Activated NK cells (CD16+/CD56+/CD3-/CD69+/FasL+ or IL-18Ra+)
Time Frame: 12 weeks
|
12 weeks
|
Activated cytolytic T cells (CD8+/CD4-/CD3+/CD69+ FasL+ or IL- 18Ra+)
Time Frame: 12 weeks
|
12 weeks
|
Activated B cells (CD19+/CD25-/CD3-/CD69+)
Time Frame: 12 weeks
|
12 weeks
|
Activated Neutrophils/Monocytes (CD11b+/CD16+/CD64+/CD14+/CD45+/CD69+)
Time Frame: 12 weeks
|
12 weeks
|
Regulatory T-cells (FoxP3+/CD25+/CD4+/CD127+)
Time Frame: 12 weeks
|
12 weeks
|
Immunogenicity (anti-SB-485232 and anti-Rituximab antibodies)
Time Frame: 12 weeks
|
12 weeks
|
Anti-tumor activity (Radiographic tumor assessments)
Time Frame: 12 weeks
|
12 weeks
|
CD16 (FcγRIIIA) 158V/F genotyping
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 31, 2007
Primary Completion (Actual)
March 4, 2010
Study Completion (Actual)
March 4, 2010
Study Registration Dates
First Submitted
July 10, 2007
First Submitted That Met QC Criteria
July 10, 2007
First Posted (Estimate)
July 12, 2007
Study Record Updates
Last Update Posted (Actual)
July 26, 2017
Last Update Submitted That Met QC Criteria
July 24, 2017
Last Verified
July 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma
- Lymphoma, Non-Hodgkin
- Physiological Effects of Drugs
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Rituximab
Other Study ID Numbers
- ILI105618
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Study Data/Documents
-
Study Protocol
Information identifier: ILI105618Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Annotated Case Report Form
Information identifier: ILI105618Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Informed Consent Form
Information identifier: ILI105618Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistical Analysis Plan
Information identifier: ILI105618Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Individual Participant Data Set
Information identifier: ILI105618Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Clinical Study Report
Information identifier: ILI105618Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Dataset Specification
Information identifier: ILI105618Information comments: For additional information about this study please refer to the GSK Clinical Study Register
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma, Non-Hodgkin
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin LymphomaUnited States
-
Marker Therapeutics, Inc.RecruitingNon Hodgkin Lymphoma | Non-Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Refractory | Non-Hodgkin Lymphoma, RelapsedUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous... and other conditionsUnited States
-
Caribou Biosciences, Inc.RecruitingLymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | B Cell Non-Hodgkin's LymphomaUnited States, Australia, Israel
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRefractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Hematopoietic Cell Transplantation RecipientUnited States
-
University of WashingtonRecruitingRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin LymphomaUnited States
-
Chongqing Precision Biotech Co., LtdRecruitingNon Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin LymphomaChina
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingRefractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma | Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Cutaneous T-Cell Non-Hodgkin LymphomaUnited States
Clinical Trials on SB-485232
-
GlaxoSmithKlineCompletedMelanomaAustralia, United States
-
GlaxoSmithKlineCompletedSolid Tumor CancerUnited States
-
GlaxoSmithKlineCompletedLymphoma | Solid Tumor CancerUnited States
-
Michael John RobertsonNovartisCompletedNon-Hodgkin's LymphomaUnited States
-
GlaxoSmithKlineCompletedNeoplasms, OvarianUnited States
-
Abramson Cancer Center of the University of PennsylvaniaWithdrawnOvarian, Fallopian Tube and Peritoneal CancerUnited States
-
University of MinnesotaRecruitingCardiovascular Diseases | Type 2 DiabetesUnited States
-
GlaxoSmithKlineCompletedSchizophreniaUnited Kingdom
-
Sangamo TherapeuticsActive, not recruitingHemophilia B | Mucopolysaccharidosis I | Mucopolysaccharidosis IIUnited States
-
Medica Cor Heart HospitalUnknownCoronary Ostium Stenosis | MyonecrosisBulgaria